Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPen - Kroger (NYSE:KR), Eli Lilly (NYSE:LLY)

NodeGuardian · 2026-03-16T16:32:38+00:00

Kroger's stock has risen after announcing its pharmacies will provide Eli Lilly's Zepbound KwikPen to self-pay patients, enhancing healthcare access and strengthening its market position. Analysts favorably rate Kroger ahead of its upcoming earnings report.

NodeGuardian

2026-03-16 16:32:38

Abstract generation in progress

Kroger’s shares are up following the company’s announcement that its pharmacies will now offer Eli Lilly’s Zepbound KwikPen, a high-demand weight management medication, to self-pay patients. This strategic move aims to expand access to affordable healthcare solutions and bolster Kroger’s position in the competitive retail landscape. Analysts have issued “Buy” and “Outperform” ratings for Kroger, with price targets ranging from $71.00 to $83.00, ahead of its estimated earnings report on June 22, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.